Gilead Sciences, Inc.

NASDAQ:GILD

Drug Manufacturers - General

Healthcare
$168.98 -2.14%

-$2.69 today

Market cap
$209.59B
Beta
0.33
P/E (TTM)
16.5
EPS (TTM)
$7.42
Dividend yield
2.62%
52W Low $104.46High $157.29

Volume 4.82M

Average 6.78M

GILD Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Gilead Sciences, Inc.NASDAQ: GILD

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income turns negative

Q2 FY2026 net income was -$2.02B, compared with $1.96B a year earlier. Trailing-twelve-month net income was $5.24B. Over 3 fiscal years it compounded at +22.8% a year.

Context

  • Net income amounted to 28.9% of revenue in FY2025, up 27.2 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 18 analysts of -$1.24B (-114.6%) for the fiscal year ending Dec 2026, a slowdown from the +1672.9% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$2.02B-200.0% QoQ
Last fiscal yearDec 2025
$8.51B+1672.9% YoY
LTMJun 2026
$5.24B-17.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-203.1%-10.2%+192.9 pp
1 year+1672.9%-114.6%-1787.5 pp
3-year CAGR+22.8%+16.4%-6.4 pp
5-year CAGR+14.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
8.51B USD
Year-over-year change
+1672.9%
4-year CAGR
+8.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How GILD compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -17.0% is the 6th highest of 10, against a peer median of -6.4%.
  • Net income amounts to 17.2% of revenue for GILD, versus a peer median of 16.2%.
GILD Competitors
Net Income for GILD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LLYEli Lilly and CompanyLTM Jun 2026$26.71B USD+93.6%+49.0%33.5%
JNJJohnson & JohnsonLTM Sep 2026$16.1B USD-35.9%+14.3%16.2%
NVSNovartis AGLTM Jun 2026$12.76B USD-6.4%+32.5%22.9%
AZNAstraZeneca PLCLTM Sep 2026$11.82B USD+15.4%+59.9%19.0%
ABBVAbbVie Inc.LTM Jun 2026$6.32B USD+66.4%-29.1%9.8%
GSKGSK plcLTM Jun 2026£5.62B GBP+41.0%+0.6%16.9%
GILDGilead Sciences, Inc.LTM Jun 2026$5.24B USD-17.0%+22.8%17.2%
PFEPfizer Inc.LTM Jun 2026$4.37B USD-59.4%-37.2%6.9%
SNYSanofiLTM Jun 2026€3.96B EUR-46.8%-11.2%8.1%
MRKMerck & Co., Inc.LTM Jun 2026$3.17B USD-80.7%+7.9%4.8%
Peer median (excluding GILD) —-6.4%+7.9%16.2%

Competitors are the stored peer set for GILD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income6.2B4.59B5.67B480M8.51B
Depreciation & Amortization2.05B2.1B2.69B2.77B2.76B
Deferred Income Tax(116M)(1.55B)(962M)(1.84B)160M
Stock-Based Compensation635M644M766M835M894M
Change in Working Capital489M(1.76B)(2.3B)(880M)(3.95B)
Accounts Receivables313M(406M)157M139M(367M)
Inventory11M(310M)(842M)(426M)(1.04B)
Accounts Payables(118M)226M(347M)290M(132M)
Other Working Capital283M(1.27B)(1.27B)(883M)(2.41B)
Other Non-Cash Items2.13B5.05B2.15B9.47B1.64B
Operating Cash Flow11.38B9.07B8.01B10.83B10.02B
Capital Expenditures(579M)(728M)(585M)(523M)(563M)
Acquisitions (Net)(1.58B)(1.8B)(1.15B)(4.84B)(1.07B)
Purchases of Investments(3.9B)(1.94B)(2.37B)(736M)(4.07B)
Sales of Investments2.91B2B1.84B2.59B909M
Other Investing Activities19M(1M)058M3M
Investing Cash Flow(3.13B)(2.47B)(2.27B)(3.45B)(4.79B)
Debt Repayment(4.75B)(1.5B)(270M)1.49B(1.79B)
Common Stock Issued169M309M232M422M408M
Common Stock Repurchased(546M)(1.4B)(1B)(1.15B)(1.92B)
Dividends Paid(3.61B)(3.71B)(3.81B)(3.92B)(4B)
Other Financing Activities(145M)(173M)(278M)(281M)(440M)
Financing Cash Flow(8.88B)(6.47B)(5.13B)(3.43B)(7.75B)
Effect of Forex Changes(35M)(63M)57M(40M)92M
Net Change in Cash(659M)74M673M3.91B(2.43B)
Free Cash Flow10.81B8.34B7.42B10.31B9.46B

Gilead Sciences, Inc.

NASDAQ:GILD

Intrinsic Alpha fair value

Locked

Current Price

$168.98

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.